DPP4 and endothelial dysfunction: In vivo studies added important knowledge about the action of gliptins on atherosclerosis and, interestingly, have suggested that DPP4 inhibition has GLP-1-independent effects, possibly through regulation of other enzyme substrates, acting on attenuation of endothelial dysfunction and atherogenesis [17].